Ariana Pelosci | Authors


Pembrolizumab Alone Shows Best Response in NSCLC With 90% or Higher PD-L1 Expression

June 07, 2022

Treatment with pembrolizumab monotherapy demonstrated the best response in patients with non–small cell lung cancer and a PD-L1 tumor proportion score of 90% or more, according to a correlative analysis conducted with 3-years of follow-up.

PFS Improvement With Frontline Rucaparib Maintenance Shown in Ovarian Cancer, Regardless of HRD Status

June 06, 2022

Patients with platinum-sensitive ovarian cancer treated with maintenance rucaparib in the ATHENA-MONO trial showed a significant improvement in progression-free survival when compared with placebo in the first-line setting, regardless of HRD status.

First-line Niraparib Improves PFS in Ovarian Cancer

May 18, 2022

An individualized starting dose of niraparib, determined by weight and platelet count, continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status,